AGC Biologics and Evax Partner to Advance Promising Equine Allergy Vaccine Candidate
The CDMO supports clinical stages using its Heidelberg site’s microbial-based biologics services
Seattle, Sept. 07, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with Evax, a developer of equine vaccines to treat chronic diseases, respiratory disorders and allergies. Through this partnership, Evax advances its Antigen VLP Conjugate product into the clinical stage, and AGC Biologics will supply cGMP support for the pivotal studies.
AGC Biologics is providing services at its Heidelberg facility using microbial-based protein biologics systems. The project covers Process Development and Clinical Manufacturing for the Evax Antigen-VLP Conjugate product.
The Evax drug candidate is focused on treating summer eczema, also called sweet itch or insect bite hypersensitivity (IBH), which is one of the most prevalent allergic skin diseases in horses. It manifests as chronic relapsing seasonal allergic dermatitis (inflammatory reaction of the skin).
“For many equine diseases only limited therapeutic treatment options are available with sometimes poor efficacy,” said Dr. Antonia Gabriel, CEO and Founder of Evax. “We believe in this product and are ready to display its abilities in the clinical stages. Further, AGC Biologics and the capabilities at its Heidelberg site are an ideal fit to help guide us through this important phase of the journey.”
AGC Biologics’ Heidelberg facility has more than 20 years of experience delivering a wide range of microbial programs for developers at various stages. To date, it has supported over 100 different microbial processes for different projects, and produced two commercial products. In addition, the site is the CDMO’s Center of Excellence for Plasmid DNA (pDNA) and messenger RNA (mRNA) production, playing a vital role in the company’s global Cell and Gene Therapy services offering.
“The specialized work that Evax is performing for the equine market is truly unique and we are happy to be supporting this important program,” said JB Agnus, Chief Business Officer of AGC Biologics. “This partnership shows the true depth of our services. Thanks to our strong global network, we feel we can support any clinical and commercial projects with reliable, innovative and cost competitive solutions.”
AGC Biologics’ microbial services use various technologies and scales, and the CDMO has successfully expressed antibody fragments, growth factors, antigens, enzymes, virus-like-particles (VLPs), and other proteins. The company has experience with E. coli and Pichia microbial expression platforms, and it uses multiple modes of expression—including secretion (yeast), periplasmic secretion, soluble intracellular expression, and inclusion bodies.
To learn more about the company and its biologics and cell and gene services, visit www.agcbio.com.
About EVAX
EVAX develops new equine vaccines to treat chronic diseases, allergies, and respiratory disorders. For many equine diseases only limited therapeutic treatment options are available with sometimes poor efficacy. Hence, there is a major need for new, innovative, specific and efficacious equine therapeutics. Our mission is to transfer human standards of care into horses at an affordable price. The company is committed to the development of Equine Vaccines and Innovative Healthcare for Horses. To learn more visit https://www.evax.ch/en/.
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,500 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. To learn more, visit www.agcbio.com.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
RevoluGROUP Announces CEO and Director Stepping Down3.5.2024 00:25:00 CEST | Press release
VANCOUVER, British Columbia and BARCELONA, Spain., May 02, 2024 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX- V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) ("RevoluGROUP") today announced CEO and Director, Gavin McMillan, will be stepping down from his positions, effective immediately. Gavin joined the Company in August 2023 and served as CEO for over six months. During his leadership, McMillan has been instrumental in focusing on the continued development of the API-driven Payment-as-a-Service (PaaS) model, which has continued to expand through key white-label partnerships and joint venture agreements and enhancing revenue streams. In a statement, Bernard Lonis, the Chairman of the Board, acknowledged McMillan's vital contributions and leadership, stating, "We owe a great deal of gratitude to Gavin for his dedication and the continued strong foundation he has helpedtobuildforRevoluGROUP'sfuture. We wish Gavin the best in his future endeavors." The Board has commenced a comprehensi
Novotech Appoints Commercial and Clinical Life Sciences Specialist to Head Up Global Drug Development Consulting Team2.5.2024 23:00:15 CEST | Press release
BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has appointed Scott Schliebner as Vice President and Global Head, Drug Development Consulting (DDC). Novotech’s Chief Medical Officer Dr. Judith Ng-Cashin stated: “We welcome Scott to the medical and scientific team. He is a proven strategic, innovative, and business focused life sciences executive with ~30 year of experience across the biopharma and CRO sectors. He brings valuable leadership to our world-class DDC team, a full-service global drug development and strategic regulatory team providing comprehensive "inception to approval" services.” The DDC partners with biotechs to optimize a fit-for purpose therapeutic development strategy that both advances the development program and creates value for the company. To do this, DDC leverages CMC/manufa
Brookfield Reinsurance Completes Acquisition of AEL2.5.2024 22:10:00 CEST | Press release
BROOKFIELD, NEWS, May 02, 2024 (GLOBE NEWSWIRE) -- Brookfield Reinsurance (NYSE, TSX: BNRE, BNRE.A) and American Equity Investment Life Holding Company (NYSE: AEL) (“AEL”) today announced the completion of Brookfield Reinsurance’s acquisition of AEL in a cash and stock transaction valued at $56.50 per AEL share. AEL’s leading fixed annuity business bolsters Brookfield Reinsurance’s expanding insurance operations and increases its insurance assets under management to over $100 billion. Jon Bayer, Managing Partner at Brookfield Reinsurance said, “We are excited to welcome AEL to our organization as we continue to grow, diversify and scale our retirement services capabilities. AEL’s strong franchise and track record of serving policyholders and distribution partners, coupled with the scale of our existing platform and offerings, will position us well for the next phase of growth.” Brookfield Reinsurance expects to maintain AEL’s headquarters in Des Moines, Iowa, and its growth in the fixe
Fortinet Reports First Quarter 2024 Financial Results2.5.2024 22:05:43 CEST | Press release
First Quarter 2024 Highlights Total revenue of $1.35 billion, up 7% year over yearService revenue of $944 million, up 24% year over yearGAAP operating margin of 23.7%Non-GAAP operating margin of 28.5%1Cash flow from operations of $830 millionFree cash flow of $609 million1 SUNNYVALE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Fortinet® (Nasdaq: FTNT), a global cybersecurity leader driving the convergence of networking and security, today announced financial results for the first quarter ended March 31, 2024. “We are diligently executing on our strategy announced six months ago to leverage our scale, go-to-market capabilities, customer-first focus, and engineering expertise to capitalize on the fast-growing Unified SASE and Security Operations markets while continuing to gain market share in Secure Networking,” said Ken Xie, Founder, Chairman and Chief Executive Officer of Fortinet. “We believe our Unified SASE offering is the most comprehensive in the industry and we are well-positioned
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results2.5.2024 22:05:00 CEST | Press release
Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (U.S.) by our partner, Jazz PharmaceuticalsExpected initiation of a Phase 3 clinical trial for zanidatamab in the second half of 2024, for breast cancer patients who have progressed on trastuzumab deruxtecan (T-DXd), by our partner, Jazz Pharmaceuticals Two planned investigational new drug (IND) and foreign equivalent submissions in 2024 for ZW191 and ZW171Acceptance of an abstract for zanidatamab in BTC at the American Society of Clinical Oncology (ASCO) annual meeting submitted by our partner, Jazz PharmaceuticalsPresentation of five abstracts at the American Association for Cancer Research (AACR) ann